MX366178B - Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. - Google Patents

Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.

Info

Publication number
MX366178B
MX366178B MX2015000754A MX2015000754A MX366178B MX 366178 B MX366178 B MX 366178B MX 2015000754 A MX2015000754 A MX 2015000754A MX 2015000754 A MX2015000754 A MX 2015000754A MX 366178 B MX366178 B MX 366178B
Authority
MX
Mexico
Prior art keywords
nucleic acids
proteins
antibodies
btnl3 proteins
btnl3
Prior art date
Application number
MX2015000754A
Other languages
English (en)
Spanish (es)
Other versions
MX2015000754A (es
Inventor
A Arnett Heather
S Escobar Sabine
M Swanson Ryan
L Viney Joanne
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48906512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX366178(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2015000754A publication Critical patent/MX2015000754A/es
Publication of MX366178B publication Critical patent/MX366178B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0013—Therapeutic immunisation against small organic molecules, e.g. cocaine, nicotine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
MX2015000754A 2012-07-19 2013-07-18 Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. MX366178B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261673639P 2012-07-19 2012-07-19
PCT/US2013/051097 WO2014015148A1 (en) 2012-07-19 2013-07-18 Human btnl3 proteins, nucleic acids, and antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2015000754A MX2015000754A (es) 2015-04-16
MX366178B true MX366178B (es) 2019-07-01

Family

ID=48906512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000754A MX366178B (es) 2012-07-19 2013-07-18 Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.

Country Status (7)

Country Link
US (4) US20150166630A1 (enExample)
EP (1) EP2875046B2 (enExample)
JP (5) JP6448056B2 (enExample)
CN (1) CN104703999A (enExample)
AU (3) AU2013292510A1 (enExample)
MX (1) MX366178B (enExample)
WO (1) WO2014015148A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
WO2010094499A1 (en) 2009-02-20 2010-08-26 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
CN111875703B (zh) 2009-11-11 2024-06-04 安斯泰来制药股份有限公司 密蛋白6(cldn6)特异性的抗体
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
CA2832174C (en) 2011-05-13 2024-02-27 Ganymed Pharmaceuticals Ag Antibodies for treatment of cancer expressing claudin 6
EP2875046B2 (en) * 2012-07-19 2025-04-30 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
CN107630085B (zh) * 2017-10-12 2020-09-29 王丽 分子标志物在男性骨质疏松中的应用
SG11202011984UA (en) * 2018-06-05 2020-12-30 King S College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
US11098093B2 (en) 2019-01-07 2021-08-24 Shattuck Labs, Inc. Heterodimeric proteins for modulating gamma delta T cells
CN113329759A (zh) 2019-01-07 2021-08-31 沙塔克实验室有限公司 用于调节γδT细胞的异二聚体蛋白

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
DE69128253T2 (de) 1990-10-29 1998-06-18 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
ES2251120T3 (es) 1997-12-17 2006-04-16 Immunex Corporation Glicoproteinas de superficie celular asociadas a los linfomas b humanos-ulbp, adn y polipeptidos.
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DE69935248T2 (de) 1998-12-02 2007-11-08 Adnexus Therapeutics, Inc., Waltham Dna-protein fusionen sowie anwendungen derselben
ATE439592T1 (de) 1998-12-10 2009-08-15 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
EP1343820A4 (en) 2000-10-13 2005-09-14 Uab Research Foundation HUMANE SINGLE CHAIN ANTI EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY
WO2003077847A2 (en) 2002-03-12 2003-09-25 Merck & Co., Inc. Substituted amides
MXPA05006535A (es) 2002-12-23 2005-09-08 Immunex Corp Acidos nucleicos, proteinas y anticuerpos btl-ii.
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
EP1702622A1 (en) * 2005-03-18 2006-09-20 CONARIS research institute AG Soluble BTNL2 protein useful to inhibit inflammatory disorders
AR056142A1 (es) 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
EP2052088A2 (en) 2006-08-02 2009-04-29 Genizon Biosciences Genemap of the human genes associated with psoriasis
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer
EP2556086B1 (en) 2010-04-09 2015-03-04 Amgen Inc. Btnl9 proteins, nucleic acids, and antibodies and uses thereof
EP2875046B2 (en) * 2012-07-19 2025-04-30 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof

Also Published As

Publication number Publication date
US20150166630A1 (en) 2015-06-18
US20230192802A1 (en) 2023-06-22
EP2875046B1 (en) 2020-02-26
JP2022040181A (ja) 2022-03-10
EP2875046A1 (en) 2015-05-27
US20190169259A1 (en) 2019-06-06
CN104703999A (zh) 2015-06-10
AU2019250154A1 (en) 2019-10-31
US20250361283A1 (en) 2025-11-27
JP2020039369A (ja) 2020-03-19
AU2013292510A1 (en) 2015-02-05
AU2018200171A1 (en) 2018-02-01
AU2019250154B2 (en) 2021-04-22
EP2875046B2 (en) 2025-04-30
JP2018015009A (ja) 2018-02-01
MX2015000754A (es) 2015-04-16
US11459370B2 (en) 2022-10-04
JP2023184751A (ja) 2023-12-28
JP6448056B2 (ja) 2019-01-09
CA2878400A1 (en) 2014-01-23
JP2015524413A (ja) 2015-08-24
WO2014015148A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
MX2015000754A (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
EA201492101A1 (ru) Антитела против fcrn
PH12014502527B1 (en) St2 antigen binding proteins
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
PH12016500275A1 (en) Antibodies
ZA201405021B (en) Cx3cr1-binding polypeptides
MX2019007921A (es) Nuevos agentes de union a ha.
PH12016500753B1 (en) Antibodies specific to fcrn
MY166157A (en) Antibodies to bradykinin b1 receptor ligands
PH12015500752A1 (en) Her3 antigen binding proteins binding to the beta-hairpin of her3
WO2014151834A3 (en) Methods and compositions relating to anti-ccr7 antigen binding proteins
MX2015014198A (es) Anticuerpos cuyo objetivo es m-csf.
MX2016014726A (es) Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1.
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.

Legal Events

Date Code Title Description
FG Grant or registration